Sleeman Taps PGA Tour Caddie Dave Markle to Celebrate Golf's Ultimate Real One
GUELPH, ON, June 5, 2025 /CNW/ - Sleeman - the Official Beer of Golf Canada - is proud to unveil a game-changing partnership that shifts the spotlight in golf away from the pros and towards the ones behind them. Just in time for the Canadian Open, the Canadian brew has teamed up with PGA Tour caddie and one of Canada's most respected voices in the game, Dave Markle. The first-of-its-kind partnership is designed to cut through the noise and get down to what really matters - recognizing the one who carries the game, and helping Canadians play better golf.
"Behind every clutch shot is someone hauling clubs and bringing calm in the chaos. That someone? That's the caddie. Golf's ultimate real one," said Dana Brochu, Director, National Beer, Sleeman Breweries. "Sleeman has built its legacy as a genuine Canadian brand who firmly believes in celebrating real, down-to-earth people. To us, a real one is someone who shows up when it matters, tells it like it is and stays true to their word. No one embodies that spirit more than Dave Markle. His grounded outlook, unwavering work ethic, and genuine love for the game—and for life—make him the perfect ambassador for Sleeman as we continue raising a glass to the real ones, both on and off the course."
To kick off the partnership, Sleeman and Markle are getting straight to work. Their first initiative? Cleaning up Canada's golf game. This June, golfers are invited to submit a video to Sleeman of their swing or ask about any part of their game they're working on in exchange for personalized feedback from Markle himself - real advice from a real one. One lucky participant will even win the chance to play nine holes with Markle as their personal caddie.
Sleeman's partnership with Markle comes on the heels of a newly launched brand platform, 'Real Ones Know' that's all about creating a sense of community and recognition among everyday down-to-earth people to show them that Sleeman is on their side. It also marks Sleeman's fourth consecutive year as a proud partner of Golf Canada, with Sleeman Clear 2.0 returning as its Official Beer and activations at The Canadian Open. This year, fans can expect more than just beer tents—they'll get real golf insights and swing advice straight from one of the game's most trusted insiders.
"In golf, the moment you start trying to play like someone else, you lose what makes your game work," said Dave Markle. "The best players I've seen are the ones who know their game and trust it—tempo, mindset, the whole thing. It's not about being perfect; it's about being real. That's why I'm proud to team up with Sleeman. They're not trying to be anything they're not—and in this game, that kind of honesty goes a long way."
Looking to save a few strokes this season? Canadians 19 years of age and older can participate by sending a video of their swing or burning questions via direct message to Sleeman on Instagram. In return, a limited number of participants will receive a video back from Markle analyzing their swing or offering tips tailored to their game. For full details on how to enter and to learn more about Sleeman's partnership with Dave Markle, visit www.realonesknow.ca.
About Sleeman Breweries
Sleeman Breweries, based in Guelph, Ontario, is Canada's third-largest national brewer. Reopened in 1988 by John W. Sleeman using original family recipes dating back to 1834, the brewery blends historic craftsmanship with innovation. From pioneering clear bottles to launching a cream ale in a lager-dominated market, Sleeman has always done things differently. Today, Sleeman's brewmasters bring over 100 years of combined experience to crafting award-winning beers. A small-batch brewhouse drives continued innovation in styles and flavour, keeping alive the spirit of five generations of brewing tradition. Sleeman's portfolio includes top Canadian brands like Sleeman Original Lager, Sleeman Clear 2.0, Sleeman Clear 2.0 Lime, Sleeman Honey Blonde and Sleeman Zero+ Lager. For more information, visit www.sleeman.ca.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
NATO spending plan challenging for Canada
Opinion How much is $150 billion as an annual government expense? It's three times the annual Canada Health Transfer, the mechanism Ottawa uses to support provincial health care. In fact, $150 billion as an annual expenditure dwarfs the entirety of federal transfers each year ($100 billion) for health, social programs and equalization. In other words, it's a lot of money. However, it's also apparently the price of keeping one particularly bombastic president at bay. Adrian Wyld / The Canadian Press files Prime Minister Mark Carney U.S. President Donald Trump has frequently stated that a massive increase in defence spending is table stakes for getting preferential treatment on trade issues. The connection between defence spending and trade was made patently clear last week in The Hague, where the leaders of NATO countries held their annual summit. NATO has been on tenterhooks since January, when Trump warned member nations that if they did not meet the (then) two per cent of GDP spending target, the world's biggest defence spender would abandon the alliance. Trump complained, and with some justification, that some NATO countries (including Canada) are failing to meet the existing target. Canada currently spends just over $62.7 billion on defence. In one of his first acts, Prime Minister Mark Carney pumped another $9 billion into the defence budget, which pushed Canada to the two per cent threshold. However, just as Canada finally fulfilled its NATO spending obligation, the target moved. Late last month, NATO nations endorsed a plan — first suggested by Trump — to increase defence spending to five per cent of GDP over the next decade, broken down into 3.5 per cent on direct military spending (troops, weapons, munitions) and 1.5 per cent on 'militarily adjacent' things such as roads and bridges, emergency health care and cybersecurity. For Canada, the new target would eventually mean $150 billion annually on direct and adjacent military spending. Carney said that over the next five years, Canada can demonstrate increased military spending rather easily in the adjacent category of projects, which could include investments in ports, highways, telecommunications and the development of critical minerals. It's the direct military spending that has the potential to cast a long shadow over the federal budget. Weekday Evenings Today's must-read stories and a roundup of the day's headlines, delivered every evening. Carney said if Canadians support the new spending target, it will mean 'considerations about what less the federal government can do in certain cases.' What federal programs could be impacted? Carney would not say, but when you're measuring increased defence spending in the tens of billions of dollars, you would need to start taking away from Ottawa's other hefty budget lines: transfers to the provinces, infrastructure spending and such programs as Employment Insurance, the Canada Child Benefit and federal pension funds. There is lots of wiggle room in this 10-year commitment. NATO leaders created a 10-year runway to achieve the new spending target knowing full well that in about three and a half years, Trump should cease to be president ('should,' because Trump has mused about finding a way to sidestep term limits). Should a Trump acolyte continue his legacy, it's quite likely the pressure to increase military spending will continue. However, there is one very important caveat in this equation that should be considered: the U.S. currently does not meet the new five per cent target. The U.S. spends roughly 3.5 per cent of GDP on its military, which is the most among NATO allies but still hundreds of billions of dollars below the new target. The U.S. will have to endure a domestic debate about whether this kind of spending is acceptable, even in a world that has been ravaged by conflict. It is often said that time heals all wounds. Perhaps time could, as well, play a major role reducing the need to spend more money on the tools of war by spending a bit more time and money on finding ways to stabilize global security.
Cision Canada
2 hours ago
- Cision Canada
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research organization (CRO) industry for its outstanding achievements in clinical trial innovation, strategic execution, and client-centric delivery. This recognition highlights Novotech's leadership in enabling biotech and small to mid-sized pharma companies to accelerate therapeutic development globally through flexible, high-touch, and technologically advanced clinical trial services. The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors worldwide. "Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for biotech and small to midsize pharma, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials," said Unmesh Lal, vice president, healthcare & life sciences at Frost & Sullivan. With nearly three decades of experience, Novotech has built a robust reputation for delivering high-quality clinical trials at speed. Its integrated service model encompasses regulatory consulting, clinical operations, biometrics, data management, and medical writing, allowing clients to streamline their development pipelines from early phase to post-marketing studies. Through a powerful combination of local knowledge, scientific expertise, and digital capabilities, Novotech continues to enhance trial efficiency, patient recruitment, and regulatory outcomes. Novotech's dedication to advancing clinical research is further reflected in its strategic acquisitions and partnerships. The company's expansions into the United States and Europe marked a significant milestone in building a globally unified platform while preserving its excellence in APAC operations. Novotech's sustained growth trajectory is driven by its deep alignment with sponsors' evolving needs and its commitment to scientific excellence and operational agility. "We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide," said Dr. John Moller, chief executive officer, Novotech Novotech's unwavering commitment to client experience strengthens its position in the market. By streamlining service delivery, enabling real-time trial visibility through advanced digital systems, and maintaining continuity across project teams, the company delivers exceptional client satisfaction. Its regionalized, partner-led delivery model and localized expertise ensure regulatory compliance and cultural alignment—key factors that drive trial success in various markets. Frost & Sullivan commends Novotech for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and client-first culture are shaping the future of biotech clinical trials and driving tangible outcomes that matter to patients and sponsors. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, client satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, client service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini Singh E: [email protected] About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Edmonton Journal
5 hours ago
- Edmonton Journal
Top-ranked U.S. women cruise to win over Canada in soccer friendly
Article content The American women were coming off back-to-back 4-0 wins over No. 25 Ireland. Article content U.S. coach Emma Hayes made 10 changes to the team that beat Ireland Sunday, essentially reverting to the same starting lineup as in the first Ireland match last Thursday. Forward Lynn Biyendolo was the only holdover. Article content Article content Canada went into Wednesday's contest with a 4-53-9 all-time record against the U.S. in a rivalry that dates back to 1986 when the Canadian women's program was established. The Canadians have not won on American soil since Nov. 11, 2000. Article content In their most recent meeting, last April at the SheBelieves Cup in Columbus, Ohio, the two teams played to a 2-2 draw before the U.S. won a penalty shootout 5-4. The Americans also won by penalty shootout in the game before that, the CONCACAF W Gold Cup semifinal in March 2024. Article content Article content Canada's last win over the U.S. was a 1-0 decision in the Tokyo Olympic semifinal in August 2021. That was the Americans' first loss to their northern neighbours since March 2001, in the group stage of the Algarve Cup. Article content It was 29 C, feeling like 32 C at kickoff for the clash of the last two Olympic champions. Article content The U.S. came out with purpose and Biyendolo, put behind the Canadian defence in the sixth minute, failed to find the target with an attempted chip. Two minutes later, Canada's defence was cut open again with Sheridan stopping Biyendolo's header. Article content After going down 1-0, Canada threatened for the first time in the 20th minute only to see U.S. goalkeeper Claudia Dickey, in just her second senior appearance, deny Jordyn Huitema from in close. Article content Sheridan stopped Alyssa Thompson in the 23rd minute after another Canadian defensive breakdown. Article content Article content The U.S. had 63% possession in the first half and outshot Canada 8-5 (6-2 in shots on target). Article content Early in the second half, the Americans queued up to take a shot on the Canadian goal, winning ball after ball. Article content Stoney sent on Nichelle Prince and Shelina Zadorsky in the 62nd minute. Simi Awujo, Holly Ward, Marie Levasseur and Annabelle Chukwu followed off the Canadian bench. Article content Biyendolo hit the crossbar in the 80th minute as the Canadian defence was found wanting again. Article content Appointed in January, Stoney saw her record with Canada fall to 6-2-1. The lone previous loss was a 1-0 setback April 8 at the hands of No. 32 Argentina in Langford, B.C. — 'a game we should never lose,' said Stoney. Article content
